share_log
Moomoo 24/7 ·  Mar 20, 2024 10:08
IGC Pharma Announces Interim Results For IGC-AD1 In Reducing Alzheimer's Agitation; Study Achieved Primary End Point Demonstrating Clinical And Statistically Significant Reductions Compared To Placebo In Agitation Associated With Dementia Due To Alzheimer's Disease
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment